Giant cell arteritis      

FOI REFERENCE: 24089  FOI DATE: 8^th May 2024   

Q1. Does your trust or health board treat giant cell arteritis (GCA)?  If not, please provide the name of the hospital or trust that you refer GCA patients to. Yes

Q2. In the past 3 months, how many patients with a primary diagnosis of GCA (ICD10 codes M31.5 or M31.6) were:

• Admitted as an inpatient

Jan 2024-Mar 2024:        6

Apr 2023-Mar 2024:       32

• Treated in A&E

Feb 2024-Apr 2024:         *
May 2023-Apr 2024:       12

Q3. How many patients were treated by the rheumatology department in the past 3 months with the following: 

• Tocilizumab – for any disease                                   69
• Tocilizumab for rheumatoid arthritis (RA) only          65
• Tocilizumab for giant cell arteritis (GCA) only           *

Q4. How many patients were treated by the ophthalmology department (for any disease) in the past 3 months with Tocilizumab?   0

Q5. How many patients were treated in A&E in the past 3 months for giant cell arteritis (GCA) with Tocilizumab?  0

*This relates to low numbers between 1 and 5. Under section 40 (ii) of the Freedom of Information Act 2000, statistically low numbers that potentially identify personal data are required to be withheld because of the Trusts obligation to protect personal data under the Data Protection Act 2018